Cargando…

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors

Skeletal-related events (SREs) including pain, fractures, and hypercalcemia are a major source of morbidity for cancer patients with bone metastases. The receptor activator of NF-κB ligand (RANKL) is a key mediator of osteoclast formation and activity in normal bone physiology as well as cancer-indu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown-Glaberman, Ursa, Stopeck, Alison T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333824/ https://www.ncbi.nlm.nih.gov/pubmed/22532777 http://dx.doi.org/10.2147/BTT.S20677

Ejemplares similares

Impact of denosumab on bone mass in cancer patients
por: Brown-Glaberman, Ursa, et al.
Publicado: (2013)

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach
por: Jacobson, Dionna, et al.
Publicado: (2022)

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
por: Brown-Glaberman, Ursa, et al.
Publicado: (2016)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Response to letter to the Editors—Safety of long-term denosumab therapy
por: Stopeck, Alison T., et al.
Publicado: (2016)

Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study
por: Mizuta, Kohei, et al.
Publicado: (2023)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
por: Cadieux, Benoit, et al.
Publicado: (2022)

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
por: Li, Huiping, et al.
Publicado: (2023)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study
por: Diel, Ingo J., et al.
Publicado: (2022)

Role of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases
por: Park, Sun H., et al.
Publicado: (2018)

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
por: von Moos, Roger, et al.
Publicado: (2015)

Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis
por: Haslbauer, Ferdinand, et al.
Publicado: (2019)

Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study
por: Abousaud, Aseala I., et al.
Publicado: (2020)

Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: A case report
por: Wang, Guannan, et al.
Publicado: (2019)

Giant-cell tumor of bone: treatment options and role of denosumab
por: Singh, Arun S, et al.
Publicado: (2015)

A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
por: Okuma, Satoe, et al.
Publicado: (2020)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
por: Zhang, Zhicai, et al.
Publicado: (2017)

Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications
por: Jiang, Cindy Y, et al.
Publicado: (2022)

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
por: Matza, Louis S, et al.
Publicado: (2013)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland
por: Lothgren, Mickael, et al.
Publicado: (2013)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
por: Smith, M. R., et al.
Publicado: (2015)

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
Publicado: (2015)

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
por: Li, Wei, et al.
Publicado: (2023)

Bone metastases and skeletal-related events from neuroendocrine tumors
por: Van Loon, Katherine, et al.
Publicado: (2015)

Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials
por: Poon, Michael, et al.
Publicado: (2012)

Heterogeneity of Circulating Tumor Cell Neoplastic Subpopulations Outlined by Single-Cell Transcriptomics
por: Pauken, Christine M., et al.
Publicado: (2021)

Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
por: Focaccia, Marco, et al.
Publicado: (2021)

Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours
por: Durán, I., et al.
Publicado: (2013)

'Salvage Treatment' of Aggressive Giant Cell Tumor of Bones with Denosumab
por: Vaishya, Raju, et al.
Publicado: (2015)

A Recurrent Giant Cell Tumor of Bone Treated with Denosumab
por: Stadler, Nicola, et al.
Publicado: (2015)

Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis
por: Egbert, Ryan Carlisle, et al.
Publicado: (2017)

Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls
por: Li, Hengyuan, et al.
Publicado: (2020)

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2018)

Complications of bone metastases from malignant melanoma
por: Zekri, Jamal, et al.
Publicado: (2017)

Importance of antiresorptive therapies for patients with bone metastases from solid tumors
por: Talreja, Draupadi B
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0moj26vn4vvssv85mcu0occrgf